BWAY Stock — Brainsway Ltd

Brainsway Ltd (BWAY)

Updated October 16, 2026.

BWAY is a Stock. Total return is 106.3% over the past 7.5 years, 87.9 points behind SPY at 194.2%.

Brainsway Ltd develops and sells noninvasive neurostimulation treatments for mental health and neurological disorders, using deep transcranial magnetic stimulation technology to treat conditions including major depression, obsessive-compulsive disorder, PTSD, and others; it serves psychiatrists, hospitals, and medical centers globally from its headquarters in Jerusalem, Israel. The company does not currently distribute dividends to shareholders. This security appeals primarily to growth-oriented investors in the healthcare technology sector rather than those seeking current income.

BWAY performance versus SPY

Price and return data through 2026-10-16.

Total return is 106.3% over the past 7.5 years, 87.9 points behind SPY at 194.2%. Over the past year its total return — price change plus distributions reinvested — is 43.0%. Its deepest 1-year drawdown was 33.4%.

BWAY key facts

Asset type

Stock

Asset class

Equity

Inception date

04/17/2019

Distribution frequency

None

Last close

$11.44 (as of 2026-10-16)

Market cap

$460,494,194

Average volume

66289.0

Beta

0.099

Payout ratio

0.0%

P/E ratio

49.74

Forward P/E

17.9211

EPS

$0.23

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BWAY risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 33.4%.

Who may consider BWAY — and who may not

It is a weaker fit for investors who need monthly cash flow (BWAY does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BWAY

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions